NTRK2 and injury: The intravitreal delivery of the 29D7 TrkB agonist antibody delays retinal ganglion cell death in models of acute and chronic retinal injury [49,50], whilst intracerebroventricular administration prior to initiation of a neonatal hypoxic-ischemic brain injury in rats significantly increased neuronal survival and behavioral recovery [31].